Ionis CBO takes over Akcea as CEO, president and COO head out the door

exit
The moves come nearly a year after Akcea’s first FDA nod, for the hereditary transthyretin-mediated amyloidosis (hATTR) treatment Tegsedi. (Christian Guiton/iStock)

Just like that, Akcea Therapeutics’ top leadership is out. CEO Paula Soteropoulos, President Sarah Boyce and Chief Operating Officer Jeff Goldberg are bidding the company adieu. Akcea’s board installed Ionis CBO Damien McDevitt as interim CEO. 

Soteropoulos and Boyce gave up their board seats, with Joseph “Skip” Klein III, an Ionis board member, and Michael Yang, Acadia’s chief commercial officer, replacing them. Soteropoulos and Goldberg will stay on as “advisors” to aid the transition, Akcea said in a statement. 

The moves come nearly a year after Akcea’s first FDA nod, for the hereditary transthyretin-mediated amyloidosis (hATTR) treatment Tegsedi. Its second drug, Waylivra (volanesorsen) scored EU approval earlier this year, but hasn’t fared quite as well stateside. It squeaked past an FDA advisory panel in a 12-8 vote in May 2018 only to receive a Complete Response Letter from the agency three months later. 

Webinar

CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

RELATED: Rejected by the FDA, Ionis and Akcea's Waylivra finds new life with EU approval

“Damien brings significant expertise and a track record of success in both science and business from his tenure in the pharmaceutical and biotechnology industries,” said Akcea Chairman Christopher Gabrieli, in the statement. “He also has a deep understanding of the Akcea portfolio and the underlying antisense technology. Skip and Michael augment the investor, business and commercialization expertise that is already on our board. The addition of these three individuals allows us to continue to build on the launches of TEGSEDI and WAYLIVRA and invest in our promising pipeline.” 

RELATED: 2017’s Fiercest Women in Life Sciences | Sarah Boyce—Ionis

Tegsedi and Waylivra are two of four programs that Ionis offloaded when it spun out Akcea in 2015. And there’s more where that came from: Ionis is “renewing and deepening its commitment to Akcea as it plans to license new antisense drugs to the company,” Gabrieli said. Akcea could pick up programs from other companies too, he said. 

“We thank Paula, Sarah and Jeff for building a strong commercial organization that can now support the development and commercialization of additional drugs,” said Stanley Crooke, M.D., Ph.D., the chairman of Ionis, in the statement. “Akcea is well positioned to optimize the commercial success of TEGSEDI and WAYLIVRA and to support the development and the launch of additional drugs from our pipeline, including AKCEA-TTR- LRx, which will begin a Phase 3 program shortly.”

Editor's note: This story was edited to correct Sarah Boyce's role at Akcea.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.